Castle Biosciences Inc., a cancer-focused molecular diagnostics company, today announced the completion of an $11.8 million financing. The round was led by new investor HealthQuest Capital, with participation by Castle Biosciences’ current investors including Mountain Group Capital and Affiliates, Longfellow Venture Partners and others. In conjunction with this financing, Garheng Kong, M.D., Ph.D., Managing Partner of HealthQuest Capital, will join Castle Biosciences’ Board of Directors.Continue reading
Category Archives: AZBio News
W.J. “Jim” Lane, Mayor of Scottsdale, Arizona to be honored with AZBio’s Public Service Award
W.J. “Jim” Lane, Mayor of Scottsdale, Arizona, has been selected as the recipient of the 2014 AZBio Public Service award by the Arizona BioIndustry Association.Continue reading
Paradigm Initiates Genomic Profiling for Pharmatech’s AccessPPM Cancer Registry Program
Novel clinical trial matching protocol enables greater access to genomic profiling and targeted clinical studies for cancer patients nationwide.Continue reading
NAU Reseachers Study Link Between Uranium Exposure And Skin Cancer,
After years of delving deep into DNA and researching ways in which metal damage may lead to cancer, a team of researchers is taking a step back to look at the surface where one answer may have been all along.Continue reading
NIH awards BAI, Mayo $8.3 million on continued study of the risk of developing Alzheimer’s disease at older ages
Health Canada Approves ABRAXANE® Plus Gemcitabine for First-Line Treatment of Patients with Metastatic Pancreatic Cancer
High unmet need addressed with first new approved treatment in eighteen yearsContinue reading
Biodesign’s Arntzen using tobacco as a way to make and deliver a promising vaccine for the Ebola virus
Charlie Arntzen has worked tirelessly on new platforms to deliver vaccines. He has focused on plant-based vaccine delivery systems, testing a wide range of plants as possible “manufacturing platforms” for vaccines for the developing world.Continue reading
Ventana paves the way for companion diagnostic early phase clinical trials in China to advance patient care
TUCSON, Ariz., Aug. 5, 2014 /PRNewswire/ — Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, today announces a new agreement with Quintiles, Inc. to offer College of American Pathology (CAP)-standard companion diagnostic testing services in China for pharmaceutical and biotech companies conducting early phase clinical trials. This is great news for patients as China is one of the only countries in the world that requires all patient samples be tested in China, even those used in clinical trials.Continue reading
UA Researchers Exploring If Diet Can Make You Live Longer
UA Researchers Study Increasing Lifespan and Immune FunctionContinue reading
Tech Launch Arizona Breaking Records For Commercialization
A Record Year for Technology Commercialization at the UA. In the last fiscal year, the UA executed 39 exclusive licenses and 72 total licenses, among other successes.Continue reading